+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
ID07436793

Comparing Megestrol Acetate and Micronized Progesterone for Treating Endometrial Cancer or Precancer Before Surgery in Women

Led by New Mexico Cancer Research Alliance · Updated on 2026-07-02

140

Participants Needed

4

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of two types of progestinsmegestrol acetate and micronized progesteronein women diagnosed with endometrial cancer or precancers of the uterus known as atypical endometrial hyperplasia. This phase II trial aims to understand how these hormone therapies affect the malignant tissue before surgery and to identify biomarkers that may guide future treatments for endometrial cancer. Participants are randomly assigned to one of two groups. One group receives oral megestrol acetate twice daily, and the other receives oral micronized progesterone once daily. Both treatments begin 21 to 24 days before the participants scheduled hysterectomy, which is the standard surgical treatment involving removal of the uterus. During the study, participants undergo biopsy or curettage before starting the hormone therapy and then have surgery to remove the uterus. After surgery, participants are followed up for 30 to 45 days. The main measure of the study is how the tissue responds to the hormone treatment from biopsy through to the hysterectomy specimen, helping researchers understand the effectiveness of each progestin.

CONDITIONS

Brief Title

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here